<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017575</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-022</org_study_id>
    <nct_id>NCT01017575</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)</brief_title>
  <official_title>A Phase 2a Study of Daclatasvir in Combination With Peginterferon Alfa-2a(Pegasys®) and Ribavirin (Copegus®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify at least 1 dose of Daclatasvir, that when combined
      with peginterferon-alfa (PegIFNα) and ribavirin (RBV) for the treatment of chronically
      infected HCV genotype 1 treatment-naïve and non-responder to standard of care subjects is
      safe, well tolerated, and efficacious
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</measure>
    <time_frame>From Week 4 up to Week 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>eRVR was defined as undetectable hepatitis C virus (HCV) RNA ie, HCV RNA &lt;15 IU/mL, the lower limit of detection at both Weeks 4 and 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virologic Response (RVR)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>RVR was defined as undetectable hepatitis C virus (HCV) RNA ie, HCV RNA &lt;15 IU/mL, the lower limit of detection at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Complete Early Virologic Response (cEVR)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>cEVR was defined as hepatitis C virus RNA &lt;15 IU/mL at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 and Follow-up Week 24</measure>
    <time_frame>Follow up Week 12, Follow up Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR at Follow-up Week 12 (SVR12) and SVR at Follow-up week 24 (SVR24) was defined as hepatitis C virus (HCV) RNA &lt;15 IU/mL at follow-up Weeks 12 and 24.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died.</measure>
    <time_frame>From Baseline up to 30 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not has a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Grade 3 to 4 Laboratory Abnormalities</measure>
    <time_frame>From screening up to Week 12 (treatment period)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinically significant change in marked laboratory abnormalities (Grade 3 to 4) included: Aspartate aminotransferase (AST)- Grade 3 as &gt;5.0 to 10.0*Upper Limit of Normal (ULN), Grade 4 as &gt;10.0*ULN; Hemoglobin- Grade 3 as 7.0 to 8.9 g/dL, Grade 4 as &lt;7.0 g/dL; Neutrophils- Grade 3 as 0.5 to 0.749*10^9/L, Grade 4 as &lt;0.5*10^9/L; Lymphocytes- Grade 3 as 0.35 to 0.499*10^9/L, Grade 4 as &lt;0.35*10^9/L; Platelets- Grade 3 as 25000 to 49999*10^9/L, Grade 4 as &lt;25000 10^9/L; white blood cells (WBC) - Grade 3 as 1000 to 1499*10^9/L, Grade 4 as &lt;1000*10^9/L and Lipase- Grade 3 as 3.1-5.0*ULN, Grade 4 as &gt;5.0*ULN.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Responder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Responder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablets, Oral, 10 mg, daily, 24-48 weeks</description>
    <arm_group_label>Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablets, Oral, 60 mg, daily, 24-48 weeks</description>
    <arm_group_label>Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, daily, 48 weeks</description>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks</description>
    <arm_group_label>Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <other_name>Pegasys®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks</description>
    <arm_group_label>Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <arm_group_label>Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)</arm_group_label>
    <other_name>Copegus®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects chronically infected with hepatitis C virus (HCV) genotype 1

          -  HCV RNA viral load ≥ 10*5* IU/mL (100,000 IU/mL) at screening

          -  The current standard of care naïve or non-responder

        Key Exclusion Criteria:

          -  Cirrhosis

          -  HCC

          -  Co-infection with hepatitis B virus (HBV), HIV-1 or HIV-2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chiba-Shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kurume-Shi</city>
        <state>Fukuoka</state>
        <zip>8300011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Okayama-Shi</city>
        <state>Okayama</state>
        <zip>7008558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-Shi</city>
        <state>Osaka</state>
        <zip>5438555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-Shi</city>
        <state>Osaka</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Musashino-Shi</city>
        <state>Tokyo</state>
        <zip>180-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 13, 2015</lastchanged_date>
  <firstreceived_date>November 19, 2009</firstreceived_date>
  <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
